A sensitive label-free electrochemical immunosensor for detection of cytokeratin 19 fragment antigen 21-1 based on 3D graphene with gold nanopaticle modified electrode.
A sensitive label-free electrochemical immunosensor for detection of cytokeratin 19 fragment antigen 21-1 based on 3D graphene with gold nanopaticle modified electrode.
复制标题
DOI：
10.1016/j.talanta.2017.09.020
复制
发表时间：
2018-02
期刊：
影响因子：
6.1
通讯作者：
Yan Zeng;Jing Bao;Yanan Zhao;D. Huo;Mei Chen;Mei Yang;Huan-bao Fa;Changjun Hou
中科院分区：
文献类型：
--
作者：
Yan Zeng;Jing Bao;Yanan Zhao;D. Huo;Mei Chen;Mei Yang;Huan-bao Fa;Changjun Hou
细胞角蛋白19片段抗原21-1（CYFRA 21-1）是非小细胞肺癌（NSCLC）的重要生物标志物。在此，我们首次报道了一种无标记的电化学免疫传感器，用于灵敏和选择性地检测肿瘤标志物CYFRA 21 -1。本文将三维石墨烯@金纳米颗粒（3D-G@Au）纳米复合物修饰在玻碳电极（GCE）表面，以提高免疫传感器的电导率。抗CYFRA 21 -1通过壳聚糖（CS）、戊二醛（GA）与抗CYFRA 21 -1的交联作用捕获并固定在修饰的GCE上。利用修饰电极表面抗CYFRA 21 -1抗体与CYFRA 21 -1之间特异性相互作用引起的微分脉冲伏安法（DPV）峰电流变化来检测CYFRA 21 -1。在优化的条件下，该电化学免疫传感器用于检测CYFRA 21 -1，并表现出较宽的线性范围为0.25-800 ng mL− 1和低检测限为100 pg mL−1（S/N = 3）。血清样品的回收率在95.2%~ 108.7%之间，与酶联免疫吸附试验（ELISA）的相关性小于6.6%。因此，基于3D-G@Au的免疫传感器有望在CYFRA 21 -1的临床医学诊断中发挥重要作用。
Previous studies have confirmed that cytokeratin 19 fragment antigen 21-1 (CYFRA 21-1) serves as a powerful biomarker in non-small cell lung cancer (NSCLC). Herein, we report for the first time a label-free electrochemical immunosensor for sensitive and selective detection of tumor marker CYFRA21-1. In this work, three-dimensional graphene @ gold nanoparticles (3D-G@Au) nanocomposite was modified on the glassy carbon electrode (GCE) surface to enhance the conductivity of immunosensor. The anti-CYFRA21-1 captured and fixed on the modified GCE through the cross-linking of chitosan (CS), glutaraldehyde (GA) and anti-CYFRA21-1. The differential pulse voltammetry (DPV) peak current change due to the specific interaction between anti-CYFRA21-1 and CYFRA21-1 on the modified electrode surface was utilized to detect CYFRA21-1. Under optimized conditions, the proposed electrochemical immunosensor was employed to detect CYFRA21-1 and exhibited a wide linear range of 0.25–800 ng mL−1and low detection limit of 100 pg mL−1(S/N = 3). Moreover, the recovery rates of serum samples were in the range from 95.2% to 108.7% and the developed immunosensor also shows a good correlation (less than 6.6%) with enzyme-linked immunosorbent assay (ELISA) in the detection of clinical serum samples. Therefore, it is expected that the proposed immunosensor based on a 3D-G@Au has great potential in clinical medical diagnosis of CYFRA21-1.